Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Scheuer

Pss41 - Secukinumab Significantly Reduces Psoriasis-Related Work Impairment and Indirect Costs Compared to Ustekinumab and Etanercept in Tunisia

Value in Health

English

Pss42 - Secukinumab Significantly Reduces Psoriasis-Related Work Impairment and Indirect Costs Compared to Ustekinumab and Etanercept in Morocco

English

Related publications

Modulation of Inflammatory Gene Transcripts in Psoriasis Vulgaris: Differences Between Ustekinumab and Etanercept

Journal of Allergy and Clinical Immunology

Allergy

Immunology

2019

English

Impact of HS on Work Loss, Indirect Costs and Income

British Journal of Dermatology

Dermatology

Medicine

2019

English

Pms46 Impact of Etanercept on Work and Activity Impairment in Employed Patients With Moderate to Severe Rheumatoid Arthritis

English

Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology

Dermatology

Medicine

2019

English

Psy86 - Higher Levels of Skin Clearance Are Associated With Decreased Indirect Costs Related to Productivity Loss in Patients With Moderate-To-Severe Plaque Psoriasis

English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

English

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Clinical pharmacology and therapy

2018

English

Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Scheuer

Pss41 - Secukinumab Significantly Reduces Psoriasis-Related Work Impairment and Indirect Costs Compared to Ustekinumab and Etanercept in Tunisia

Pss42 - Secukinumab Significantly Reduces Psoriasis-Related Work Impairment and Indirect Costs Compared to Ustekinumab and Etanercept in Morocco

Related publications

Modulation of Inflammatory Gene Transcripts in Psoriasis Vulgaris: Differences Between Ustekinumab and Etanercept

Impact of HS on Work Loss, Indirect Costs and Income

Pms46 Impact of Etanercept on Work and Activity Impairment in Employed Patients With Moderate to Severe Rheumatoid Arthritis

Risankizumab vs. Ustekinumab for Plaque Psoriasis

Psy86 - Higher Levels of Skin Clearance Are Associated With Decreased Indirect Costs Related to Productivity Loss in Patients With Moderate-To-Severe Plaque Psoriasis

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective